Haemonetics Corp has roughly 236.88
M in cash with 105.76
M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.64.
Our trade recommendations tool can be used to complement Haemonetics Corp advice provided by
experts. It analyzes the entity's potential to grow against your specific risk preferences and investment horizon.
Investing in Haemonetics, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Haemonetics along with other instruments in the same portfolio. Using conventional
technical analysis and
fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed
many market ups and downs, anticipate that the market will even out over time. This tendency of Haemonetics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Haemonetics. Your research has to be compared to or analyzed against Haemonetics' peers to derive any actionable benefits. When done correctly, Haemonetics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Haemonetics.
How important is Haemonetics's Liquidity
Haemonetics
financial leverage refers to using borrowed capital as a funding source to finance Haemonetics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Haemonetics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Haemonetics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Haemonetics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Haemonetics's total debt and its cash.
Haemonetics Gross Profit
Haemonetics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Haemonetics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Haemonetics Gross Profit growth over the last 10 years. Please check Haemonetics'
gross profit and other
fundamental indicators for more details.
Haemonetics Correlation with Peers
Investors in Haemonetics can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Haemonetics. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Haemonetics and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Haemonetics is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with
your current brokerage. Please check
volatility of Haemonetics for more details
Breaking down Haemonetics Indicators
Haemonetics Corp holds Efficiency (Sharpe) Ratio of -0.0931, which attests that the entity had -0.0931% of return per unit of risk over the last 3 months. Macroaxis standpoint towards determining the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and
technical indicators. Haemonetics Corp exposes twenty-eight different
technical indicators, which can help you to evaluate volatility that cannot be
diversified away. Please be advised to check out Haemonetics Corp Downside Deviation of 2.7,
market risk adjusted performance of 0.1456, and Risk Adjusted Performance of 0.068 to validate the risk estimate we provide.
Will Haemonetics Corp shareholders go ballistic after another dip?
Latest total risk alpha is at 0.44. Haemonetics Corp currently demonstrates below-average downside deviation. It has Information Ratio of 0.09 and Jensen Alpha of 0.26. However, we advise investors to further question Haemonetics Corp expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Haemonetics Corp's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Haemonetics Corp's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Haemonetics Corp Implied Volatility
Haemonetics Corp's implied volatility exposes the market's sentiment of Haemonetics Corp stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Haemonetics Corp's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Haemonetics Corp stock will not fluctuate a lot when Haemonetics Corp's options are near their expiration.
Although some other entities in the medical instruments & supplies industry are either recovering or due for a correction, Haemonetics Corp may not be performing as strong as the other in terms of long-term growth potentials. With an optimistic outlook on your 90 days horizon, it may be a good time to buy new shares of Haemonetics or increase your existing holdings in the Stock as it seems the potential growth has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Haemonetics Corp.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Haemonetics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
